Form 4: Anixa Biosciences Director Granted Stock Options

Anixa Biosciences Director Emily Gottschalk was granted 25,000 employee stock options with an exercise price of $3.18, vesting monthly starting January 31, 2026.

Summary

• Emily Gottschalk, a Director of Anixa Biosciences Inc (ANIX), acquired 25,000 employee stock options.
• The options were granted on January 5, 2026, under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
• Each option has an exercise price of $3.18.
• The options will vest and become exercisable in twelve equal monthly installments, commencing on January 31, 2026.
• The expiration date for these options is January 5, 2036.
• Following this transaction, Emily Gottschalk directly beneficially owns 25,000 derivative securities.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (stock option grant) which is generally a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain significant positive or negative financial news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options were granted under an existing and approved 2018 Share Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The options are scheduled to vest in twelve equal monthly installments beginning January 31, 2026, indicating a future schedule for the director's equity compensation to become exercisable.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Anixa Biosciences, to attract, retain, and motivate key personnel by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology, similar to how companies such as Moderna or BioNTech utilize equity incentives.
• The vesting schedule of 12 equal monthly installments is a common approach to ensure continued commitment and performance over a defined period, comparable to vesting structures seen in many tech and biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns the director's financial incentives with the company's long-term stock performance, potentially leading to increased shareholder value.
• Employees (specifically the director): Provides a significant equity incentive, enhancing retention and motivation.

Next Steps

• The options will begin vesting on January 31, 2026, in twelve equal monthly installments.

Key Dates

Keywords

Anixa Biosciences, ANIX, stock options, insider transaction, Form 4, director compensation, equity incentive plan